medigraphic.com
ISSN 0188-9796 (Print)

2011, Number 2

<< Back Next >>

Rev Endocrinol Nutr 2011; 19 (2)

Clinical, biochemical and imaging characteristics of cabergoline-resistant prolactinomas at the Hospital de Especialidades, Centro Médico Nacional Siglo XXI

Márquez-López JA, Mendoza-Zubieta V, Ramírez-Rentería C, Mercado M

Language: Spanish
References: 18
Page: 69-73
PDF size: 91.62 Kb.


ABSTRACT

Background and objectives: From 10-20% of patients with prolactinoma are resistant to dopamine agonists (DA). The aim of this study was to determine the frequency and the clinical, biochemical and imaging of prolactinomas resistant to cabergoline (CBG). Material and methods: This was a descriptive, observational, transversal study. We analyzed the records of patients of clinical S. XXI CMN prolactinomas and selected 8 patients who met the following inclusion criteria: a) Failure to normalize prolactin levels despite the use of CBG at ≥ 3 mg/week for at least 12 months and b) Picture pituitary tumor remaining compliant despite a history of at least desmasificadora surgery. Results: All cases had invasive tumors. 75% were male. In the 37.5% found a BMI over 30 kg/m2. There was a positive correlation between prolactin values at diagnosis and BMI (R = 0.76, p = 0.028). Conclusions: In our series, the most common factors associated with complete resistance to AD were: initial serum prolactin greater than 1,000 ng/mL, invasive tumor, heterogeneous, male gender and presence of overweight or obese.


REFERENCES

  1. Schlechte JA. Clinical practice. Prolactinoma. N Engl J Med 2003; 349: 2035-2045.

  2. Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin Proc 2005; 80: 1050-1057.

  3. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM et al. Diagnosis and treatment of hyperprolactinemia: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2011; 96: 273-288.

  4. Mancini T, Casanueva FF, Giustina A. Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin North Am 2008; 37: 67-99.

  5. Vernooij MW, Ikram MA, Tanghe HL et al. Incidental finding on brain MRI in the general population. N Engl J Med 2007; 357: 1821-1828.

  6. Vilar L, Freitas MC, Naves LA et al. Diagnosis and management of hyperprolactinemia: results of Brazilian multicenter study with 1,234 patients. J Endocrinol Invest 2008; 31: 436-444.

  7. Klibanski A. Clinical practice. Prolactinomas. N Engl J Med 2010; 362: 1219-1226.

  8. Colao A. The prolactinoma. Best Pract Res Clin Endocrinol Metab 2009; 23: 575-596.

  9. Guillan MP, Molitch ME, Lombardi G, Colao A. Advance in the treatment of prolactinomas. Endocr Rev 2006; 27: 485-534.

  10. Molitch ME, Elton RL, Blackwell RE, Cadwell B, Chang RJ et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 1985; 60: 698-705.

  11. Molitch ME. Medical treatment of prolactinoma. Endocrinol Metab Clin North Am 1999; 28: 143-169.

  12. Colao A, Di Sarno A, Pivonello R, di Somma C, Lombardi G. Dopamine receptor agonist for treating prolactinomas. Expert Opin Investig Drugs 2002; 11: 787-800.

  13. Colao A, Di Sarno A, Cappabianca P et al. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 2003; 349: 2023-2033.

  14. Molitch ME. Pituitary gland: can prolactinomas be cured medically? Nat Rev Endocrinol 2010; 6: 186-188.

  15. Molitch ME. Pharmacologic resistance in prolactinoma patients. Pituitary 2005; 8: 43-52.

  16. Molitch ME. The cabergoline-resistant prolactinoma patient: New challenges. J Clin Endocrinol Metab 2008: 93: 4643-4645.

  17. Colao A, Di Sarno A, Sarnacchiaro F et al. Prolactinoma resistant to standard dopamine agonist respond to cronic cabergoline treatment. J Clin Endocrinol Metab 1997; 82: 876-883.

  18. Pinero A, Marcos-Alberca P, Fortes J. Cabergoline-related severe restrictive mitral regurgitation. N Engl J Med 2005; 353: 1976-1977.




2020     |     www.medigraphic.com